Vydura 75mg (Rimegepant) Migraine Prevention - 8 Wafers

Vydura 75mg is an effective migraine treatment and prevention solution for adults. Its main active ingredient, Rimegepant, targets and diminishes the activity of the substance calcitonin gene-related peptide (CGRP). Elevated levels of CGRP have been observed in those experiencing migraines. By binding to the CGRP receptor, Rimegepant minimises its activity, helping both to:

• Halt active migraine episodes
• Lessen the occurrence of future migraine attacks when used as a preventative measure

To understand more about CGRP and its role in migraines, read this in-depth article on Medical News Today.

Vydura 75mg offers dual advantages:

1. Treatment - actively supresses ongoing migraine attacks.
2. Prevention – Reduces the frequency of migraines when consumed regularly.

Vydura has shown to be more effective than placebo in treating migraine in three main studies involving a total of around 3,500 adults. Two hours post-treatment, participants gauged their headache severity using a 4-point Likert scale where 0 indicated no pain and 3 signified severe pain.

Results revealed that 20% of Vydura users experienced no headache pain within two hours, in contrast to the 12% among placebo recipients. Vydura also effectively alleviated associated migraine symptoms such as photophobia (heightened light sensitivity), phonophobia (increased sensitivity to sound), and nausea. Roughly 36% of individuals on Vydura reported relief from at least one of these symptoms two hours after administration, whereas the number was about 27% for those on placebo.

Another study involving 747 adults, each experiencing 4 to 18 migraine episodes monthly, found Vydura’ s capability in diminishing migraine days. When participants consumed Vydura or a placebo alternatively for a span of 12 weeks, the Vydura group reported an average reduction of 4.3 migraine days in the study’s final 4 weeks, whereas the placebo group witness a decrease of 3.5 days.

Contradictions

• Do not consume if you’re allergic to Rimegepant or any of the other ingredients detailed in the patient information leaflet.

Before using Vydura, Consult Your Pharmacist or Doctor:

• Severe liver issues.

• Reduces kidney function or undergoing kidney dialysis.

Immediate Cease of Use Required If:

• Symptoms of allergic reactions like severe rashes or breathing difficulties are observed. Remember, these can appear several days post-administration.

Medication Interactions

Inform your healthcare provider if you’re consuming, or plan to consume, other medications. Some drugs can interfere with Vydura’s efficacy or vice versa. This list includes but isn’t limited to: Itraconazole, Ritonavir, Bosentan, John’s Wort, Phenobarbital, Modafinil, Fluconazole, Diltiazem, and Cyclosporin.

Pregnancy and Lactation

Consult your physician if pregnant, suspecting pregnancy, or breastfeeding before consuming Vydura.

Driving and Machinery

No known impact on one’s ability to operate machines or vehicles.

For migraine prevention, the standard dosage is one oral lyophilisate (75 mg Rimegepant) every alternate day. For active migraine treatment, a similar dose is suggested, ensuring no more than one dosage daily.

All medicines can include side effects, though they’re not universally experienced. Stop Vydura consumption and notify your doctor if any signs of allergic reactions appear. Common side effects, affecting up to 1 in 100 individuals, can be nausea.

Each Vydura oral lyophilisate is equipped with 75 mg Rimegepant. Additional ingredients encompass gelatin, mannitol, mint flavouring, and sucralose.